Search results
15 wrz 2022 · Example of an LV apical mural (laminar) thrombus (red arrows) seen on gadolinium-enhanced CMR. Note the adjacent white appearing areas indicating infarcted myocardium. CMR indicates cardiac magnetic resonance; and LV, left ventricular.
14 wrz 2022 · Is anticoagulation really indicated for laminated thrombus (not a more mobile, round, mural thrombus)? Is DOAC a reasonable alternative to warfarin for the prevention and treat-ment of LV thrombus? What management options are there in patients with persistent LV throm-bus despite therapy?
A calcified LVT was defined as a persistent left ventricular mural thrombus encapsulated by thickened and calcified endocardium. Left ventricular characteristics including left ventricular ejection fraction (LVEF), left ventricular volume, wall motion, cardiac output, and potential mechanical complications were also collected.
Etiology and Treatment of LV Thrombus. Cumulative etiologies (A) and long-term anticoagulants (B) selected for treatment of left ventricular (LV) thrombus. In-hospital mortality was 7.8%. An additional 7.8% were not initiated on long-term anticoagulation due to medical contraindications.
Abstract. Introduction Left ventricular thrombus (LVT) is a frequent complication of left ventricular systolic dysfunction (1). Incidence following acute myocardial infarction is estimated at 13–20% and up to 15% in with non-ischaemic cardiomyopathy (2, 3). Once diagnosed, guidelines recommend anticoagulation with vitamin K antagonists (VKA ...
The 2013 American College of Cardiology Foundation/AHA STEMI guidelines recommend as reasonable (Class 2a, Level of Evidence: C) 3 months of VKA therapy for patients with STEMI and asymptomatic LV mural thrombus with a target INR of 2.0-2.5 when combining OAC with DAPT. 5 The 2014 AHA/American Stroke Association stroke guidelines recommend 3 ...
Abstract: Intracardiac thrombus is a condition of increasing clinical significance not only because of its potential complications but also because of the lack of clinical evidence to guide clinicians in selecting optimal therapies.
